Latest
Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
Influence of Factor VIII Prophylaxis on Joint Health in Children With Hemophilia A
Using the PLASMIC Score to Risk Stratify Patients With Immune Thrombotic Thrombocytopenic Purpura
Gait Speed Effectively Predicts Clinical Outcomes in Older Patients With Hematologic Cancers
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Type of EBV-Infected Cells Valuable in Diagnosis of Hematologic Disease
Efficacy of Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia
Response to Iron Chelation Therapy May Predict Improvement in Transfusion-Dependent Myelofibrosis
Greater Infection Risk With Unrelated Transplant Donors in Pediatric Acute Lymphoblastic Leukemia
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Relapse Predictors in Immune Thrombotic Thrombocytopenic Purpura After Rituximab Treatment
EULAR Recommendations for Management of Henoch-Schönlein Purpura
Featured Content
Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
From Fatal to Curable: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
